Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis

Fig. 2

Network plots comparing efficacy and toxicity of neoadjuvant combination. (A): PCR (B): MPR, each circle represents an intervention as a node in the network. The size of the circle and the width of the line are proportional to the number of RCTS and comparisons, respectively, with chemotherapy serving only as a transitive node for indirect comparisons.CT: chemotherapy; Nivo-CT: nivolumab plus chemotherapy, Tori-CT: Toripalimab plus chemotherapy; Durv-CT: duvalumab plus chemotherapy, Pemb-CT: pembrolizumab plus chemotherapy; Tis-CT: Tislelizumab plus chemotherapy; Ipi + Nivo-CT: ipil-imumab plus nivolumab plus chemotherapy

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us